Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Chemoradiation vs Chemotherapy in Advanced ESCC
NCT05919030Phase 3Recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: Progression-Free Survival at 40 months. Started Jul 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05919030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919030.